<DOC>
	<DOCNO>NCT02046746</DOCNO>
	<brief_summary>The study objective evaluate renal specific oral nutrition supplement ( ONS ) aid maintain nutritional status .</brief_summary>
	<brief_title>The Effect Renal Specific Oral Nutritional Supplement Nutritional Status</brief_title>
	<detailed_description>This study unblinded , prospective , multicenter , single arm study Taiwan . Eligible subject ( see inclusion exclusion criterion Section 5.2 ) receive standard care ( include dietary counseling ) ONS supplementation ( 1-2 servings/day depend subject 's need ) 24 week ( 6 month ) . A follow visit ( phone call/medical chart review ) occur 12 month study intervention end collect mortality data , determine whether dialysis initiate , ONS use continue . Subjects inform study result available . Subjects may continue use commercially available study product recommend nephrologist , primary care physician , dietitian , subject chooses . For study enrollment define subject stratified begin consume study product ( Study Visit 1 , Month 0 ) . The target population describe may stratify follow group ( n=18 evaluable/group ) : 1 . Male CKD Stage 3b-5 without T2DM 2 . Male CKD Stage 3b-5 T2DM 3 . Female CKD Stage 3b-5 without T2DM 4 . Female CKD Stage 3b-5 T2DM In addition , subject enrol , retrospective data ( previous 6 12 month ) identical study variable collect . Retrospective data collection focus follow measure , however , data point expect available : - Serum albumin - SGA - Compliance protein intake guideline - Compliance energy intake guideline - Hand grip strength - Anthropometrics ( weight , height , BMI ) - Quality Life ( WHOQOL-BREF Taiwan Version ) - eGFR ( whichever equation use standard care ) - Serum creatinine - Proteinuria ( retrospective - available medical record ) - BUN - Body composition data BIA ( especially fat mass muscle mass , unit exact terminology model specific ) - C reactive protein ( CRP ) - Blood chemistry ,</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<criteria>1 . Subject , subject 's legally acceptable representative ( LAR ) , voluntarily sign date informed consent form ( ICF ) , approve IEC/IRB , provide Health Insurance Portability Accountability Act ( HIPAA ) 2 . Subject &gt; 18 year age . 3 . Subject diagnose Chronic Kidney Disease ( CKD ) classify Stages 3b 5 . 4 . Subject eGFR 45 10 ml/min/1.73m2 screening . 5 . Subject male nonpregnant female least six week postpartum nonlactating . 6 . Subject CKD either : diagnose Type 2 Diabetes Mellitus ( T2DM ) OR diagnose T2DM change glycemic medication ( dose type ) least 2 month prior screen 7 . Subject serum albumin 3.0 g/dl screening . 8 . Subject BMI 30 kg/m2 . 9 . If diagnose T2DM , subject A1c level 9.0 % screening . 10 . Subject schedule expect receive dialysis next 18 month . 11 . Subject 's life expectancy 18 month determine study physician . 12 . Subject willing follow protocol describe . 13 . With regard ONS use subject must qualify one following : 1. naïve ONS 2. subject already prescribe another ONS study product , consume 8 serving last 28 day prior screen , undergo washout period ( 3 week ) 3. subject already prescribe study product , consume ≤ 8 serving last 28 day prior screen , poor daily compliance ( &lt; 75 % ) , undergo washout period ( 3 week ) 4. subject already prescribe study product , consume 12 serving daily , &gt; 75 % compliance , &lt; 3 month , require washout period , retrospectively include study protocol ( provide proper record obtain ) 1 . Subject type 1 diabetes . 2 . Subject consider malnourished ( SGA = 1 3 ) . 3 . Subject receive intravenous albumin treatment within last 6 month . 4 . Subject overt symptomatic peripheral neuropathy , retinopathy , autonomic neuropathy . 5 . Subject poorly control chronic hypertension 6 . Subject major surgery , inpatient outpatient , require &gt; 7 day hospitalization last 3 week prior screen visit , 7 . Subject know chronic/contagious infectious disease , clot bleed disorder , active malignancy 8 . Subject miss , amputation , limb . 9 . Subject significant cardiovascular event 10 . Subject know obstruction gastrointestinal tract , inflammatory bowel disease , short bowel syndrome form gastrointestinal disease 11 . Subject currently diagnose , history severe dementia delirium , eat disorder , history significant neurological psychiatric disorder , alcoholism , substance abuse condition may interfere study product consumption compliance study protocol procedures 12 . Subject currently consume , refrain taking , medications/dietary supplements/herbal preparation substance , 13 . Subject know allergic intolerant ingredient find study product . 14 . Subject consider unsuitable study base study physician 's assessment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>